{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:14:22Z","timestamp":1772169262148,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s13555-025-01360-y","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:57:41Z","timestamp":1739966261000},"page":"681-695","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Benefits and Satisfaction with Apremilast Treatment in Patients with Psoriasis Affecting the Genital Area: Secondary Analysis of the APPRECIATE Study"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct02740218","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-9961","authenticated-orcid":false,"given":"Neuza","family":"da Silva Burger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy V.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Methodios","family":"Typou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3080-497X","authenticated-orcid":false,"given":"Rachel","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0270-0372","authenticated-orcid":false,"given":"David","family":"Neasham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1797-0510","authenticated-orcid":false,"given":"Myriam","family":"Cordey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"issue":"2","key":"1360_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377\u201385. https:\/\/doi.org\/10.1038\/jid.2012.339.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1360_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/bjd.17403","volume":"181","author":"M Augustin","year":"2019","unstructured":"Augustin M, Sommer R, Kirsten N, et al. Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. Br J Dermatol. 2019;181(2):358\u201365. https:\/\/doi.org\/10.1111\/bjd.17403.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1360_CR3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/ced.12805","volume":"41","author":"JF Merola","year":"2016","unstructured":"Merola JF, Li T, Li W-Q, Cho E, Qureshi AA. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41(5):486\u20139. https:\/\/doi.org\/10.1111\/ced.12805.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1360_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2340\/00015555-0988","volume":"91","author":"KAP Meeuwis","year":"2011","unstructured":"Meeuwis KAP, de Hullu JA, Massuger LFAG, van de Kerkhof PCM, van Rossum MM. Genital psoriasis: a systematic literature review on this hidden skin disease. Acta Derm Venereol. 2011;91(1):5\u201311. https:\/\/doi.org\/10.2340\/00015555-0988.","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"1360_CR5","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1080\/09546634.2018.1453125","volume":"29","author":"KAP Meeuwis","year":"2018","unstructured":"Meeuwis KAP, Potts Bleakman A, van de Kerkhof PCM, et al. Prevalence of genital psoriasis in patients with psoriasis. J Dermatolog Treat. 2018;29(8):754\u201360. https:\/\/doi.org\/10.1080\/09546634.2018.1453125.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1360_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/ajd.14227","volume":"65","author":"M Wu","year":"2024","unstructured":"Wu M, Fischer G. Adult genital psoriasis: an updated review for clinicians. Australas J Dermatol. 2024;65(3):e1\u201312. https:\/\/doi.org\/10.1111\/ajd.14227.","journal-title":"Australas J Dermatol"},{"key":"1360_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/PTT.S169389","volume":"8","author":"EJ Yang","year":"2018","unstructured":"Yang EJ, Beck KM, Sanchez IM, Koo J, Liao W. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis (Auckl). 2018;8:41\u20137. https:\/\/doi.org\/10.2147\/PTT.S169389.","journal-title":"Psoriasis (Auckl)"},{"issue":"6","key":"1360_CR8","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jaad.2015.02.1127","volume":"72","author":"C Ryan","year":"2015","unstructured":"Ryan C, Sadlier M, de Vol E, et al. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol. 2015;72(6):978\u201383. https:\/\/doi.org\/10.1016\/j.jaad.2015.02.1127.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1360_CR9","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1111\/j.1365-2133.2011.10249.x","volume":"164","author":"KAP Meeuwis","year":"2011","unstructured":"Meeuwis KAP, de Hullu JA, van de Nieuwenhof HP, et al. Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol. 2011;164(6):1247\u201355. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10249.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1360_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1046\/j.1365-4362.1997.00032.x","volume":"36","author":"MA Gupta","year":"1997","unstructured":"Gupta MA, Gupta AK. Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol. 1997;36(4):259\u201362. https:\/\/doi.org\/10.1046\/j.1365-4362.1997.00032.x.","journal-title":"Int J Dermatol"},{"issue":"4","key":"1360_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s13555-017-0204-3","volume":"7","author":"JC Cather","year":"2017","unstructured":"Cather JC, Ryan C, Meeuwis K, et al. Patients perspectives on the impact of genital psoriasis: a qualitative study. Dermatol Ther (Heidelb). 2017;7(4):447\u201361. https:\/\/doi.org\/10.1007\/s13555-017-0204-3.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1360_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000338858","volume":"224","author":"KAP Meeuwis","year":"2012","unstructured":"Meeuwis KAP, van de Kerkhof PCM, Massuger LFAG, de Hullu JA, van Rossum MM. Patients\u2019 experience of psoriasis in the genital area. Dermatology. 2012;224(3):271\u20136. https:\/\/doi.org\/10.1159\/000338858.","journal-title":"Dermatology"},{"issue":"11","key":"1360_CR13","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris\u2014part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461\u201398. https:\/\/doi.org\/10.1111\/jdv.16915.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1360_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1\u201310. https:\/\/doi.org\/10.1007\/s00403-010-1080-1.","journal-title":"Arch Dermatol Res"},{"key":"1360_CR15","unstructured":"Amgen Europe B.V. Otezla [summary of product characteristics]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/otezla-epar-product-information_en.pdf. Accessed Mar 25, 2024."},{"issue":"1","key":"1360_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase\u00a0III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis ESTEEM 1). J Am Acad Dermatol. 2015;73(1):37\u201349. https:\/\/doi.org\/10.1016\/j.jaad.2015.03.049.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1360_CR17","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52\u00a0weeks: a phase\u00a0III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387\u201399. https:\/\/doi.org\/10.1111\/bjd.14164.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1360_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jdv.14015","volume":"31","author":"K Reich","year":"2017","unstructured":"Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase\u00a0IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017;31(3):507\u201317. https:\/\/doi.org\/10.1111\/jdv.14015.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1360_CR19","first-page":"221","volume":"17","author":"L Stein Gold","year":"2018","unstructured":"Stein Gold L, Bagel J, Lebwohl M, et al. Efficacy and safety of apremilast in systemic- and biologic-naive patients with moderate plaque psoriasis: 52-week results of UNVEIL. J Drugs Dermatol. 2018;17(2):221\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1360_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/jdv.16431","volume":"35","author":"M Augustin","year":"2021","unstructured":"Augustin M, Kleyn CE, Conrad C, et al. Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. J Eur Acad Dermatol Venereol. 2021;35(1):123\u201334. https:\/\/doi.org\/10.1111\/jdv.16431.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1360_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2021.05.010","author":"P Herranz","year":"2021","unstructured":"Herranz P, Trasobares L, Mateu A, et al. Caracterizaci\u00f3n y resultados de pacientes tratados con apremilast en la pr\u00e1ctica cl\u00ednica habitual espa\u00f1ola: resultados del estudio APPRECIATE. Actas Dermosifiliogr (Engl Ed). 2021. https:\/\/doi.org\/10.1016\/j.ad.2021.05.010.","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"6","key":"1360_CR22","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jaad.2013.07.040","volume":"69","author":"JA Walsh","year":"2013","unstructured":"Walsh JA, McFadden M, Woodcock J, et al. Product of the physician global assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol. 2013;69(6):931\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2013.07.040.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1360_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis\u2013oral therapy with a new retinoid. Dermatologica. 1978;157(4):238\u201344. https:\/\/doi.org\/10.1159\/000250839.","journal-title":"Dermatologica"},{"issue":"3","key":"1360_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x.","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"1360_CR25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00403-009-0928-8","volume":"301","author":"M Augustin","year":"2009","unstructured":"Augustin M, Radtke MA, Zschocke I, et al. The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res. 2009;301(8):561\u201371. https:\/\/doi.org\/10.1007\/s00403-009-0928-8.","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"1360_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00403-012-1256-y","volume":"304","author":"J Feuerhahn","year":"2012","unstructured":"Feuerhahn J, Blome C, Radtke M, Augustin M. Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res. 2012;304(6):433\u201341. https:\/\/doi.org\/10.1007\/s00403-012-1256-y.","journal-title":"Arch Dermatol Res"},{"key":"1360_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12. https:\/\/doi.org\/10.1186\/1477-7525-2-12.","journal-title":"Health Qual Life Outcomes"},{"key":"1360_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1477-7525-7-36","volume":"7","author":"M Bharmal","year":"2009","unstructured":"Bharmal M, Payne K, Atkinson MJ, Desrosiers M-P, Morisky DE, Gemmen E. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36. https:\/\/doi.org\/10.1186\/1477-7525-7-36.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"1360_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4103\/ijd.ijd_754_21","volume":"67","author":"OS Yi","year":"2022","unstructured":"Yi OS, Huan KY, Har LC, Ali NM, Chiang TW. Genital psoriasis: a prospective, observational, single-centre study on prevalence, clinical features, risk factors, and its impact on quality of life and sexual health. Indian J Dermatol. 2022;67(2):205. https:\/\/doi.org\/10.4103\/ijd.ijd_754_21.","journal-title":"Indian J Dermatol"},{"issue":"4","key":"1360_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/JW9.0000000000000112","volume":"9","author":"A Gonzalez-Cantero","year":"2023","unstructured":"Gonzalez-Cantero A, Constantin MM, Dattola A, Hillary T, Kleyn E, Magnolo N. Gender perspective in psoriasis: a scoping review and proposal of strategies for improved clinical practice by European dermatologists. Int J Womens Dermatol. 2023;9(4):e112. https:\/\/doi.org\/10.1097\/JW9.0000000000000112.","journal-title":"Int J Womens Dermatol"},{"issue":"3","key":"1360_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1684\/ejd.2020.3768","volume":"30","author":"N Da Silva","year":"2020","unstructured":"Da Silva N, Augustin M, Langenbruch A, et al. Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care. Eur J Dermatol. 2020;30(3):267\u201378. https:\/\/doi.org\/10.1684\/ejd.2020.3768.","journal-title":"Eur J Dermatol"},{"issue":"4","key":"1360_CR32","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.16736","volume":"179","author":"C Ryan","year":"2018","unstructured":"Ryan C, Menter A, Guenther L, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase\u00a0IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018;179(4):844\u201352. https:\/\/doi.org\/10.1111\/bjd.16736.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1360_CR33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jaad.2023.10.020","volume":"90","author":"JF Merola","year":"2024","unstructured":"Merola JF, Parish LC, Guenther L, et al. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: results from DISCREET, a phase\u00a03 randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2024;90(3):485\u201393. https:\/\/doi.org\/10.1016\/j.jaad.2023.10.020.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1360_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13276","volume":"33","author":"SM Mueller","year":"2020","unstructured":"Mueller SM, Itin PH, Navarini AA, et al. The relationship between PASI and DLQI with itch, stress, and depression: do we need additional decision-making tools in psoriasis? Dermatol Ther. 2020;33(3):e13276. https:\/\/doi.org\/10.1111\/dth.13276.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1360_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s13555-021-00628-3","volume":"12","author":"TM Klein","year":"2022","unstructured":"Klein TM, Blome C, Kleyn CE, et al. Real-world experience of patient-relevant benefits and treatment satisfaction with apremilast in patients with psoriasis: an analysis of the APPRECIATE study. Dermatol Ther (Heidelb). 2022;12(1):81\u201395. https:\/\/doi.org\/10.1007\/s13555-021-00628-3.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"1360_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235091","volume":"15","author":"N Da Silva","year":"2020","unstructured":"Da Silva N, Augustin M, Langenbruch A, et al. Sex-related impairment and patient needs\/benefits in anogenital psoriasis: difficult-to-communicate topics and their impact on patient-centred care. PLoS ONE. 2020;15(7):e0235091. https:\/\/doi.org\/10.1371\/journal.pone.0235091.","journal-title":"PLoS ONE"},{"issue":"5","key":"1360_CR37","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3899\/jrheum.160115","volume":"43","author":"SY Paek","year":"2016","unstructured":"Paek SY, Thompson JM, Qureshi AA, Merola JF, Husni ME. Comprehensive Assessment of the Psoriasis Patient (CAPP): a report from the GRAPPA 2015 annual meeting. J Rheumatol. 2016;43(5):961\u20134. https:\/\/doi.org\/10.3899\/jrheum.160115.","journal-title":"J Rheumatol"},{"issue":"3","key":"1360_CR38","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/bjd.17505","volume":"180","author":"C Ryan","year":"2019","unstructured":"Ryan C. Genital psoriasis: the failure of dermatologists to identify genital involvement. Br J Dermatol. 2019;180(3):460\u20131. https:\/\/doi.org\/10.1111\/bjd.17505.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1360_CR39","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s13555-021-00536-6","volume":"11","author":"JJ Hong","year":"2021","unstructured":"Hong JJ, Mosca ML, Hadeler EK, Brownstone ND, Bhutani T, Liao WJ. Genital and inverse\/intertriginous psoriasis: an updated review of therapies and recommendations for practical management. Dermatol Ther (Heidelb). 2021;11(3):833\u201344. https:\/\/doi.org\/10.1007\/s13555-021-00536-6.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"1360_CR40","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s13555-018-0257-y","volume":"8","author":"KM Beck","year":"2018","unstructured":"Beck KM, Yang EJ, Sanchez IM, Liao W. Treatment of genital psoriasis: a systematic review. Dermatol Ther (Heidelb). 2018;8(4):509\u201325. https:\/\/doi.org\/10.1007\/s13555-018-0257-y.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01360-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01360-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01360-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T08:04:20Z","timestamp":1741939460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01360-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1360"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01360-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Neuza da Silva Burger has no conflicts of interest to declare. Rachel Sommer received honorary fees for participation in advisory boards from Amgen. Matthias Augustin participated in clinical trials, received honorary fees and financial support for scientific lectures and presentations on national and international congresses from Amgen, as well as from other pharmaceutical companies. Myriam Cordey and Kathy V Tran are employees and stockholders of Amgen Inc. David Neasham is employed by Amgen UK Limited. Methodios Typou was contracted employee of Amgen UK Limited at the time of the study and is currently employee of Protasys Limited.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The APPRECIATE study was approved by the relevant ethics committees: Ethik Kommission Medizinische Universit\u00e4t Wien, Austria; Freiburger Ethik-Kommission International, Germany; Hospital Research Ethics Committee, University College Hospital, Galway, Ireland; Regionala Etikpr\u00f6vningsn\u00e4mnden i Stockholm, Sweden; Comit\u00e9 cantonal d\u2019\u00e9thique de la recherche sur l\u2019\u00eatre humain, Switzerland; West Midlands\u2014South Birmingham Research Ethics Committee, UK. The research was conducted according to the principles expressed in the Declaration of Helsinki of 1964, as revised in 2008.Informed consent was obtained from participants before data collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}